Tregzi Approved — Orca Bio Opens a New Lane in Cell Therapy

Roche just beat both approved KRAS G12C inhibitors in a head-to-head Phase 3 — and hit overall survival at interim in a population where most trials wouldn't even power for it.

AstraZeneca goes back to CSPC for a $1.7 billion kidney disease deal, Abivax surges on $920 million and cleared cancer concerns, and Scribe Therapeutics files for an IPO. Let's get into it.

Welcome to The Pharma Closeout for Thursday, July 2nd, 2026. I'm Alex Mercer.

And I'm Maya Patel.

Top story — Roche dropped head-to-head superiority data in KRAS G12C non-small cell lung cancer today. The Phase 3 Krascendo 1 study randomized 338 adults — all previously treated — to divarasib once daily versus sotorasib once daily or adagrasib twice daily. Primary endpoint, progression-free survival. Key secondary, overall survival. Both met. Both statistically significant, with improvements Roche described as clinically meaningful. Safety profile held consistent — no new signals. The G12C mutation runs in roughly 14 percent of NSCLC cases, a poor-prognosis population where divarasib already carries Breakthrough Therapy and Orphan Drug designations. Roche plans to submit this data to health authorities and present at an upcoming medical congress.

The study architecture is what separates this from a standard positive readout. Roche powered Krascendo 1 for superiority against both approved drugs — not placebo, not investigator's choice. And overall survival crossed significance at the interim analysis, not the pre-planned final cut. In a second-line population randomized against active comparators, the monitoring committee doesn't stop a trial early unless the survival separation is large enough to make continued randomization ethically unjustifiable. Roche is holding the actual curves for a congress presentation, but the statistical framework already narrates the story.

Roche's CMO Levi Garraway framed it directly — these results should establish divarasib as a new standard of care. If you're Amgen running Lumakras or BMS running Krazati, the differentiation argument for your molecule just shifted from an open question to a defensive position.

I'd pump the brakes on calling it fully defensive. Amgen and BMS hold the installed prescribing base, the real-world evidence libraries, and the payer contracts that come with years of market presence. Superiority data shifts the burden of proof — no question. But that transition plays out across formulary cycles, not overnight.

That's the right distinction — transition, not verdict. But every NCCN update and formulary review from here forward becomes a head-to-head conversation, and Roche walks in with the data advantage. Even before share moves, the posture has changed.

The deeper read is that this standard-of-care challenge is emerging while the KRAS space itself fragments. Revolution Medicines shared Phase 1 combination data today — zoldonrasib paired with daraxonrasib in pancreatic cancer — supporting a planned Phase 3. Different mutation, different tumor, same trajectory: more entrants, more data, more pressure on everyone to differentiate. Roche just staked the clearest clinical differentiation anyone has produced in G12C — and with it, raised the evidentiary bar for anyone else claiming best-in-class. When the full survival curves hit a congress, that's when the commercial recalibration starts.

Shifting to the deal side — and AstraZeneca is back with CSPC Pharmaceutical for the second time in six months. This time a collaboration worth up to $1.7 billion to develop siRNA candidates for chronic kidney diseases. CSPC receives $30 million upfront — the rest tied to development and sales milestones, plus single-digit royalties. And this drops while China-biotech partnerships face heightened political scrutiny at the BIO conference over potential regulatory restrictions. Let's bring in Marcus Webb on this one.

Abivax surged as much as ten percent today on a dual catalyst. The company priced 6.4 million ADSs at $125 each on July 1st, and the greenshoe exercise announced this morning pushed total proceeds to $920 million. But the bigger driver was clinical — Phase 3 safety data from ABTECT Part 2 addressed the cancer concerns that hammered the stock in early June.

Those concerns stripped more than forty percent off the stock when initial malignancy cases surfaced. Today's exposure-adjusted incidence rates — 1.09 per hundred patient-years at the 25 milligram dose, 1.37 at the 50 — sit at the upper boundary of published ulcerative colitis background rates. Disease-associated, not drug-associated. That reframing is precisely what obefazimod's FDA filing narrative needs. The open question is whether the agency considers this integrated database sufficient or asks for longer follow-up. And raising $920 million through a cancer safety scare is itself a strong institutional endorsement.

Rapid fire on a few more. BridgeBio locked in up to $1 billion from Sixth Street and KKR for three upcoming launches. Ipsen is acquiring Memo Therapeutics for up to $800 million — a kidney infection drug that adds to roughly $2.5 billion in committed deal spend this year. And Fairmount Healthcare Fund exited $300 million of Oruka Therapeutics at $84.43 a share. Stock dipped after hours, recovered above $93 intraday. Market absorbed the block.

And Scribe Therapeutics filed for a Nasdaq IPO late today. This year's IPO class has produced several of the largest biotech offerings since 2022, but most were later-stage companies carrying clinical data packages. A preclinical gene-editing platform is a fundamentally different risk proposition. How Scribe prices will reveal whether institutional appetite stretches past the de-risked names — or whether the window is narrower than the headline volume suggests.

Good deal day. On the regulatory front, a few things moved quietly.

Here's the one that matters most. Vijay Kumar — the top gene and cell therapy regulator at CBER — is stepping down. Acting CBER Director Karim Mikhail picks up additional oversight of that review office, the same office at the center of ongoing debates about how much flexibility this agency is willing to show under new leadership.

We said in late June that if more gene therapy applications advanced this summer, the sector's regulatory risk profile could look materially different by Q3. A leadership transition in the office that processes those filings is a variable nobody was modeling. This isn't just about one vacancy — it's about review velocity when the reviewing leadership is in flux. Every sponsor with an active CBER submission should be recalibrating their timeline assumptions.

Separately — Otsuka reported long-term kidney data for Voxzact, the evidence package behind the drug's path to full approval. Specific endpoints haven't been disclosed, but the agency has been tightening the bar on confirmatory data for approval conversions. How they evaluate this submission sets the standard for other programs sitting in that queue.

And one legal development with broader reach than it'll get credit for.

A federal court halted Colorado's attempt to cap prices on Amgen's Enbrel. If that injunction survives appeal, it undermines the legal scaffolding other states have been building for drug price interventions. The state-level pricing playbook every government affairs team has been modeling just became materially less reliable.

Looking ahead — the full Krascendo 1 dataset is the marquee catalyst to track. WCLC and ESMO are both on the fall calendar, and either would be a high-impact venue. When those survival curves go public, the KRAS G12C landscape gets redrawn in data, not press release language. And keep an eye on Scribe's pricing — that'll be a real-time read on how deep this IPO window really runs.

I'm watching Orca Bio's commercial rollout of Tregzi — approved yesterday at a WAC of $428,000 for transplant patients. How payers respond to a novel regulatory T cell therapy at that price point will shape the access framework for the next wave of cell therapies lining up behind it.

And that is your Pharma Closeout for Thursday, July 2nd — Roche rewriting the KRAS playbook with head-to-head superiority data, AstraZeneca building a serial partnership with CSPC at $1.7 billion, Abivax turning a cancer scare into a $920 million raise and a double-digit rally, and a gene-editing IPO testing the depth of the market. That's a full day. If this briefing saves you time, follow us on Spotify and drop a rating — we're back tomorrow.

Lot of open threads heading into Friday — the survival curves we're still waiting on, Scribe's pricing, the CBER leadership gap. We'll be all over it. See you then.